ArticleStem cells (Dayton, Ohio)2017
Proteome and Secretome Characterization of Glioblastoma-Derived Neural Stem Cells.
Article in Stem cells (Dayton, Ohio), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 59 citations in OpenAlex.
- Meta-Analysis and Experimental Validation Identified FREM2 and SPRY1 as New Glioblastoma Marker Candidates.International journal of molecular sciences · 2018Pooled it
- Microglia Reprogramming in Glioblastoma: Stem Cell-Derived Factors as Emerging Immunomodulators.Cells · 2026Review
- Therapeutic and prognostic impact of target volume delineation in postoperative radiotherapy for high-grade glioma patients with subventricular zone involvement.Radiation oncology (London, England) · 2025Article
- Glioblastoma cells alter brain endothelial cell homeostasis and tight junction protein expression in vitro.Journal of neuro-oncology · 2025Article
- Blood-brain barrier permeability increases with the differentiation of glioblastoma cells in vitro.Fluids and barriers of the CNS · 2024Article
- Nanomechanical Signatures in Glioma Cells Depend on CD44 Distribution in IDH1 Wild-Type but Not in IDH1R132H Mutant Early-Passage Cultures.International journal of molecular sciences · 2023Article
- Diabetes alters the protein secretome of human adipose-derived stem cells and promotes tumorigenesis in hepatic cancer cells.Clinical and translational medicine · 2022Article
- SRPX Emerges as a Potential Tumor Marker in the Extracellular Vesicles of Glioblastoma.Cancers · 2022Article
- Article
- Slow Off-Rate Modified Aptamer (SOMAmer) Proteomic Analysis of Patient-Derived Malignant Glioma Identifies Distinct Cellular Proteomes.International journal of molecular sciences · 2021Article
- Role and mechanism of neural stem cells of the subventricular zone in glioblastoma.World journal of stem cells · 2021Review
- LRIG1 is a gatekeeper to exit from quiescence in adult neural stem cells.Nature communications · 2021Article
- O-GlcNAcylation protein disruption by Thiamet G promotes changes on the GBM U87-MG cells secretome molecular signature.Clinical proteomics · 2021Article
- The adaptive transition of glioblastoma stem cells and its implications on treatments.Signal transduction and targeted therapy · 2021Review
- Application of Proteomics in Cancer: Recent Trends and Approaches for Biomarkers Discovery.Frontiers in medicine · 2021Review
- A Signature of Nine lncRNA Methylated Genes Predicts Survival in Patients With Glioma.Frontiers in oncology · 2021Article
- Microglia promote glioblastoma via mTOR-mediated immunosuppression of the tumour microenvironment.The EMBO journal · 2020Article
- Different Shades of L1CAM in the Pathophysiology of Cancer Stem Cells.Journal of clinical medicine · 2020Review
- Glioblastoma hijacks microglial gene expression to support tumor growth.Journal of neuroinflammation · 2020Article
- Q-Cell Glioblastoma Resource: Proteomics Analysis Reveals Unique Cell-States are Maintained in 3D Culture.Cells · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 3 countries.
Funding
Abstract
Glioblastoma multiforme (GBM) (grade IV astrocytoma) is the most common and aggressive primary brain tumor. GBM consists of heterogeneous cell types including a subset of stem cell-like cells thought to sustain tumor growth. These tumor-initiating glioblastoma multiforme-derived neural stem (GNS) cells as well as their genetically normal neural stem (NS) counterparts can be propagated in culture as relatively pure populations. Here, we perform quantitative proteomics to globally characterize and compare total proteome plus the secreted proteome (secretome) between GNS cells and NS cells. Proteins and pathways that distinguish malignant cancer (GNS) stem cells from their genetically normal counterparts (NS cells) might have value as new biomarkers or therapeutic targets. Our analysis identified and quantified ∼7,500 proteins in the proteome and ∼2,000 in the secretome, 447 and 138 of which were differentially expressed, respectively. Notable tumor-associated processes identified using gene set enrichment analysis included: extracellular matrix interactions, focal adhesion, cell motility, and cell signaling. We focused on differentially expressed surface proteins, and identified 26 that participate in ligand-receptor pairs that play a prominent role in tumorigenesis. Immunocytochemistry and immunoblotting confirmed that CD9, a recently identified marker of adult subventricular zone NS cells, was consistently enriched across a larger set of primary GNS cell lines. CD9 may, therefore, have value as a GNS-specific surface marker and a candidate therapeutic target. Altogether, these findings support the notion that increased cell-matrix and cell-cell adhesion molecules play a crucial role in promoting the tumor initiating and infiltrative properties of GNS cells. Stem Cells 2017;35:967-980.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.